Production (Stage)
Ginkgo Bioworks Holdings, Inc.
DNA
$7.42
$0.639.28%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 48.32M | 43.85M | 89.05M | 56.21M | 37.94M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 48.32M | 43.85M | 89.05M | 56.21M | 37.94M |
| Cost of Revenue | 12.05M | 9.62M | 12.00M | 13.72M | 9.20M |
| Gross Profit | 36.27M | 34.23M | 77.04M | 42.49M | 28.74M |
| SG&A Expenses | 49.04M | 51.99M | 52.29M | 61.77M | 70.29M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 4.29M | -- | -- | 766.00K | -2.02M |
| Total Operating Expenses | 136.30M | 137.98M | 141.30M | 210.48M | 213.93M |
| Operating Income | -87.98M | -94.14M | -52.26M | -154.28M | -175.99M |
| Income Before Tax | -90.87M | -107.86M | -56.78M | -216.99M | -165.88M |
| Income Tax Expenses | 88.00K | -325.00K | -375.00K | 190.00K | 31.00K |
| Earnings from Continuing Operations | -90.96M | -107.53M | -56.40M | -217.18M | -165.91M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -90.96M | -107.53M | -56.40M | -217.18M | -165.91M |
| EBIT | -87.98M | -94.14M | -52.26M | -154.28M | -175.99M |
| EBITDA | -72.62M | -78.49M | -35.09M | -136.95M | -163.12M |
| EPS Basic | -1.68 | -2.00 | -1.08 | -4.23 | -3.31 |
| Normalized Basic EPS | -0.94 | -1.00 | -0.48 | -1.71 | -2.04 |
| EPS Diluted | -1.68 | -2.00 | -1.08 | -4.23 | -3.32 |
| Normalized Diluted EPS | -0.94 | -1.00 | -0.48 | -1.71 | -2.04 |
| Average Basic Shares Outstanding | 54.24M | 53.81M | 52.24M | 51.37M | 50.11M |
| Average Diluted Shares Outstanding | 54.24M | 53.81M | 52.25M | 51.38M | 50.13M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |